EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Consensus recommendations on management of selumetinib-associated adverse events in pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas

Amedeo A Azizi iD, Darren Hargrave, João Passos, Pierre Wolkenstein, Thorsten Rosenbaum, Claudia Santoro, Verena Rosenmayr, Thomas Pletschko, Paolo A Ascierto, Héctor Salvador Hernández

Neuro-Oncology Practice · 13.09.2024 · 11 (5) · 515-531

DOI: 10.1093/nop/npae038 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Neuro-Oncology Practice, online erschienen am 27.04.2024. Verfasst von Amedeo A Azizi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics and Adolescent Medicine, Division of Neonatology, Pediatric Intensive Care and Neuropediatrics; Comprehensive Center for Ped…. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Alexion, Alexion AstraZeneca Rare Disease.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Selumetinib is the first approved treatment for pediatric patients with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibromas (PN) in the EU and US, as well as in multiple other countries. Evidence for the management of selumetinib-associated adverse events (AEs) is mostly limited to clinical trials and expanded-access programs. We gathered a panel of European healthcare practitioners with clinical experience prescribing selumetinib and/or managing pediatric patients with NF1-PN to provide recommendations on the prevention and management of AEs.

Methods

A modified Delphi approach was used to develop the recommendations among the group of experts. Initial statements were developed from a literature review of current management recommendations and regulatory reports. The panel refined the statements and rated the extent to which they agreed with them in 2 sessions and a follow-up survey. The panel comprised 2 pediatric neuro-oncologists, 1 pediatric oncologist, 1 pediatrician, 1 neuropediatrician, 1 oncologist, 1 neurologist, 2 psychologists, and 1 dermatologist.

Results

The experts agreed on the relative frequency and impact of AEs potentially associated with selumetinib. Consensus-level agreement was reached for 36 statements regarding the prevention and management of AEs potentially associated with selumetinib. Experts recommended treatments for AEs based on their experience.

Conclusions

The development of a variety of consensus statements indicates expert agreement on best practices for the prevention and management of AEs potentially associated with selumetinib in pediatric patients with NF1-PN. These events are generally manageable and should be considered alongside treatment benefit. Information sharing is warranted as further experience is gained.

Schlagwörter

Stichwörter der Autor:innen

adverse event managementneurofibromatosis type 1pediatricplexiform neurofibromasselumetinib

Autor:innen und Institutionen

  • Department of Pediatrics and Adolescent Medicine, Division of Neonatology, Pediatric Intensive Care and Neuropediatrics; Comprehensive Center for Pediatrics; Comprehensive Cancer Center, Medical University of Vienna, Vi…
  • University College London Great Ormond Street Institute for Child Health, London, UK.
  • Instituto Português Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal.
  • Henri-Mondor Hospital, APHP, UPEC, Créteil, France.
  • Department of Pediatrics and Adolescent Medicine, Sana Kliniken Duisburg, Duisburg, Germany.
  • Neurofibromatosis Referral Center, Department of Women's and Children's Health and General and Specialized Surgery, University of Campania "Luigi Vanvitelli", Naples, Italy.

ORCID-Profile: Amedeo A Azizi

Förderung

  • Alexion
  • Alexion AstraZeneca Rare Disease

Zitieren

APA

Azizi, A. A., Hargrave, D., Passos, J., Wolkenstein, P., Rosenbaum, T., Santoro, C., Rosenmayr, V., Pletschko, T., Ascierto, P. A., & Hernández, H. S. (2024). Consensus recommendations on management of selumetinib-associated adverse events in pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas. Neuro-Oncology Practice, 11(5), 515-531. https://doi.org/10.1093/nop/npae038

Vancouver

Azizi AA, Hargrave D, Passos J, Wolkenstein P, Rosenbaum T, Santoro C, et al. Consensus recommendations on management of selumetinib-associated adverse events in pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas. Neuro-Oncology Practice. 2024;11(5):515-531. doi:10.1093/nop/npae038

BibTeX
@article{Azizi2024,
  author = {Azizi, Amedeo A and Hargrave, Darren and Passos, João and Wolkenstein, Pierre and Rosenbaum, Thorsten and Santoro, Claudia and Rosenmayr, Verena and Pletschko, Thomas and Ascierto, Paolo A and Hernández, Héctor Salvador},
  title = {Consensus recommendations on management of selumetinib-associated adverse events in pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas},
  journal = {Neuro-Oncology Practice},
  year = {2024},
  volume = {11},
  number = {5},
  pages = {515--531},
  doi = {10.1093/nop/npae038}
}
Kostenlos starten →